<?xml version="1.0" encoding="UTF-8"?>
<p id="p0050">The Fast Track designation addresses a broad range of products developed for use in the treatment of serious diseases with unmet medical needs, which creates whole new populations of treatable patients.
 <xref rid="bib17" ref-type="bibr">
  <sup>17</sup>
 </xref> Recently approved drugs that were granted the Fast Track designation include triclabendazole for patients with fascioliasis, and esketamine for patients with treatment-resistant major depression. There was a cumulative total of 29 approvals for all products given a Fast Track designation through December 2019.
 <xref rid="bib18" ref-type="bibr">
  <sup>18</sup>
 </xref>
</p>
